Novo Nordisk is a large-cap pharmaceutical company with exceptional 71% return on equity, 37% net margins, and 24% revenue growth, but a confirmed long-term downtrend, elevated put/call ratio of 4.95, and consecutive earnings misses create near-term caution.
Thesis pillars
- Elite Margins And Returns→Stable
- Earnings Miss Streak Deceleration→Stable
- Confirmed Long Term Downtrend↑Improving
- +1 more pillar — see the Why tab for full reasoning
Novo Nordisk A/S (NVO) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Drug Manufacturers - General
Wait for pullback to $37.20. At $39.22 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $37.20 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Weak growth.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides... Read more
Wait for pullback to $37.20. At $39.22 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $37.20 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Weak growth. Chart setup: Death cross but MACD improving, RSI 54. Fundamentals strong but target reached (1.2% upside). Wait for pullback. Score 5.6/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 20d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-10-16Recent Developments — Novo Nordisk A/S
Latest news
- NEWS Novo Nordisk A/S Stock (NVO) Moved Down by 3.07% on Apr 29: Drivers Behind the Movement - TradingKey — TradingKey negative
- NEWS Novo Nordisk (NVO) slides as investors refocus on ongoing GLP-1 pricing pressure and softer 2026 outlook - Quiver Quanti — Quiver Quantitative negative
- NEWS NVO Stock Quote Price and Forecast - CNN — CNN neutral
- NEWS Novo Nordisk stock extends pressure as market data stays thin - AD HOC NEWS — AD HOC NEWS negative
- NEWS Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance — Yahoo Finance positive
Generated 2026-10-16T01:42:06Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $37.20. At $39.22 the A.R:R is 0.2:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $37.20 (support + ATR (held)) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Analyst target reached - limited upside remaining; Weak growth. Chart setup: Death cross but MACD improving, RSI 54. Fundamentals strong but target reached (1.2% upside). Wait for pullback. Target $39.71 (+1.2%), stop $35.73 (−9.8%), A.R:R 0.2:1. Score 5.6/10, moderate confidence.
Take-profit target: $39.71 (+1.2% upside). Target $39.71 (+1.2%), stop $35.73 (−9.8%), A.R:R 0.2:1. Stop-loss: $35.73.
Analyst target reached - limited upside remaining; Weak growth; Below 200-MA, MA slope -2.2%/30d (confirmed downtrend).
Novo Nordisk A/S trades at a P/E of 9.3 (forward 11.5). TrendMatrix value score: 7.3/10. Verdict: Buy (Wait for Entry).
36 analysts cover NVO with a consensus score of 3.3/5. Average price target: $46.
What does Novo Nordisk A/S do?Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and...
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.